Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in Redwood City, California.
| Revenue (TTM) | $46.88M |
| Gross Profit (TTM) | $31.91M |
| EBITDA | $-163.39M |
| Operating Margin | -293.70% |
| Return on Equity | 33.10% |
| Return on Assets | -32.80% |
| Revenue/Share (TTM) | $0.38 |
| Book Value | $0.51 |
| Price-to-Book | 4.31 |
| Price-to-Sales (TTM) | 5.17 |
| EV/Revenue | 3.113 |
| EV/EBITDA | 1.28 |
| Quarterly Earnings Growth (YoY) | -75.50% |
| Quarterly Revenue Growth (YoY) | 62.00% |
| Shares Outstanding | $154.25M |
| Float | $132.53M |
| % Insiders | 18.54% |
| % Institutions | 38.41% |
Volatility is currently expanding